Michael J. Arthur - 24 Jan 2026 Form 4 Insider Report for Airsculpt Technologies, Inc. (AIRS)

Signature
/s/ Thomas P. Conaghan, Attorney-in-Fact
Issuer symbol
AIRS
Transactions as of
24 Jan 2026
Net transactions value
$0
Form type
4
Filing time
27 Jan 2026, 16:30:15 UTC
Previous filing
15 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Arthur Michael J Chief Financial Officer C/O AIRSCULPT TECHNOLOGIES, INC., 1111 LINCOLN ROAD, SUITE 802, MIAMI BEACH /s/ Thomas P. Conaghan, Attorney-in-Fact 27 Jan 2026 0002045264

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AIRS Common Stock, $0.001 Par Value Award $0 +147,059 $0.000000 147,059 24 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AIRS Performance Stock Units Award $0 +147,059 $0.000000 147,059 24 Jan 2026 Common Stock 147,059 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted an award of 147,059 Restricted Stock Units ("RSUs") on January 24, 2026 pursuant to the 2021 Equity Incentive Plan of AirSculpt Technologies, Inc. (the "Company"). Under the terms of the RSU award, the RSUs will vest in three equal annual installments, subject to the Reporting Person's continued employment with the Company, beginning on January 24, 2027.
F2 The Reporting Person was granted an award of 147,059 Performance Stock Units ("PSUs") on January 24, 2026 pursuant to the Company's 2021 Equity Incentive Plan. Each PSU represents a contingent right to receive one share of Company common stock. Under the terms of the PSU award, the PSUs will vest subject to a relative total shareholder return performance goal over a three-year performance period relative to the total shareholder return of the S&P Health Care Select Industry Index, with performance ranging from 0% to 200% of the target award, as determined at the end of the three-year performance period.